![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, May 05, 2017 9:07:25 AM
Date : 05/05/2017 @ 9:00AM
Source : PR Newswire (US)
Stock : Cytosorbents Corp. (MM) (CTSO)
MONMOUTH JUNCTION, N.J., May 5, 2017 /PRNewswire/ -- Positive results from the REFRESH (REduction in FREe Hemoglobin) I trial were presented on Monday, May 1, 2017 at the American Association for Thoracic Surgery (AATS) Centennial Conference in Boston, MA. REFRESH I was a prospective, randomized, controlled trial in eight major U.S. cardiac surgery centers evaluating the safety and feasibility of CytoSorb®, a blood purification technology designed to treat deadly inflammation in critically-ill and cardiac surgery patients aged 18-80 years of age, where cardiopulmonary bypass (CPB) was expected to exceed 3 hours. Complex cardiac surgery generates high levels of plasma free hemoglobin (pfHb), activated complement, and other inflammatory mediators that can trigger severe post-operative inflammation and complications such as organ dysfunction and organ failure. The CytoSorb® therapy, developed by CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy, is designed to reduce the risk of these sequelae.
Key findings of the study were:
- Valve replacement surgery (i.e. multiple valve or single valve replacement plus other procedure) was identified as the highest risk procedure for peak pfHb generation (median 123 mg/dL valve replacement vs. 61 mg/dL non-valve replacement controls)
- CytoSorb treatment achieved increasing reductions in peak pfHb levels in this population during surgery compared to control, statistically significant at 3.5h (35 mg/dL; 26% reduction) and 4.0h (61 mg/dL; 38% reduction) of CPB time (p≤0.05)
- Treatment also resulted in statistically significant decreases in activated complement C3a and C5a during surgery
- Achieved the primary safety endpoint of the study with a favorable adjudication of all serious adverse events. There were no significant differences in the rates of adverse events (AEs) or serious adverse events (SAEs) between the two groups, including 30-day mortality, and there were no unanticipated adverse device effects (UADEs) reported.
- CPB led to an expected significant drop in platelets in both groups, with treatment leading to an additional transient and stable decrease in platelets that returned to pre-treatment levels shortly after surgery. Post-operatively, blood coagulation parameters and bleeding complications were not statistically different between the two groups, and an analysis of median transfusion requirements from surgery throughout the ICU stay was not significant (packed red blood cells: 2 vs 2 units control, p=0.15; platelets: 2 vs 1 unit control, p=0.13; plasma: 1 vs 0 units control, p=0.14)
The investigators of the study have submitted a manuscript containing these and additional data for publication. As customary, more data will be made available upon potential future publication.
For more information, please visit the Company's websites at http://www.cytosorbents.com and http://www.cytosorb.com or follow us on Facebook and Twitter
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Cytosorbents Contact:
Amy Vogel
Investor Relations
732-398-5394
mailto://avogel@cytosorbents.com
Public Relations Contact:
Amy Phillips
Pascale Communications
412-327-9499
mailto://amy@pascalecommunications.com
To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/cytosorbents-announces-positive-refresh-i-trial-results-300452285.html
SOURCE CytoSorbents Corporation
Copyright 2017 PR Newswire
Recent CTSO News
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM